Seres Therapeutics, Inc. (MCRB) Social Stream
SERES THERAPEUTICS INC (MCRB) Price Targets From Analysts
The tables below show price targets and recommendations from analysts covering SERES THERAPEUTICS INC.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-12-16 | 8 | $32 | $16 | $22.833 | $1.17 | 1851.54% |
| 2022-03-01 | 7 | $32 | $16 | $22.833 | $1.17 | 1851.54% |
| 2022-05-05 | 7 | $32 | $13 | $21.333 | $1.17 | 1723.33% |
| 2022-06-08 | 7 | $29 | $7 | $17.166 | $1.17 | 1367.18% |
| 2022-08-04 | 6 | $25 | $7 | $13.8 | $1.17 | 1079.49% |
| 2022-11-03 | 6 | $25 | $9 | $13.8 | $1.17 | 1079.49% |
| 2022-12-09 | 5 | $25 | $11 | $14.6 | $1.17 | 1147.86% |
| 2023-03-08 | 7 | $25 | $10 | $13.833 | $1.17 | 1082.31% |
| 2023-03-21 | 6 | $15 | $10 | $12.4 | $1.17 | 959.83% |
| 2023-04-28 | 7 | $15 | $7 | $11.166 | $1.17 | 854.36% |
| 2023-05-10 | 7 | $15 | $7 | $11.5 | $1.17 | 882.91% |
| 2023-08-14 | 6 | $15 | $7 | $11.4 | $1.17 | 874.36% |
| 2023-08-15 | 6 | $15 | $5 | $11 | $1.17 | 840.17% |
| 2023-11-05 | 6 | $15 | $5 | $10 | $1.17 | 754.7% |
The Trend in the Analyst Price Target
MCRB's average price target has moved down $11.58 over the prior 23 months.
MCRB reports an average of 213.51% for its upside potential over the past 35 weeks.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2023-03-08 | 7 | 25 | 11 | 14.600 | 5.940 | 145.79% |
| 2023-03-08 | 6 | 25 | 11 | 14.600 | 5.940 | 145.79% |
| 2023-04-28 | 7 | 15 | 7 | 11.166 | 4.875 | 129.05% |
| 2023-06-26 | 6 | 15 | 7 | 11.400 | 5.400 | 111.11% |
| 2023-11-05 | 6 | 15 | 5 | 10.000 | 1.300 | 669.23% |
MCRB Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 1.33 | 5 | 0 | 1 | 0 | 0 | 6 |
The Trend in the Broker Recommendations
MCRB's average broker recommendation rating worsened by 0.33 over the prior 35 weeks.
Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors.
- In terms of how SERES THERAPEUTICS INC fares relative to all US stocks, note that its upside potential (average analyst target price relative to current price) is higher than 1850.01% of that group.
- MCRB has a greater average analyst price target than 330.31% of all US stocks.
- In the context of stocks in the mid market cap category, SERES THERAPEUTICS INC's variance in analysts' estimates is lower than -1459.17% of them.
- To contextualize these metrics, consider that out of stocks in the mid market cap category, SERES THERAPEUTICS INC's number of analysts covering the stock is greater than 676.07% of them.
In terms of price targets and recommendations offered by analysts, the stocks in the Pharmaceutical Products industry with the ratings most similar to SERES THERAPEUTICS INC are ASND, QURE, and XNCR.
View All Top Stocks by Price Target
Is MCRB a Buy, Hold or Sell? See the POWR Ratings now!